Stocks
Kodiak Sciences Inc.KOD
NASDAQHealthcareBiotechnology$32.89-2.52%
Price as of · delayed, not real-time
Focused on developing novel therapeutics for retinal diseases, this biopharmaceutical company has attracted investor attention for its pipeline targeting age-related macular degeneration and diabetic eye diseases. Its lead candidate, tarcocimab tedromer, is in late-stage clinical trials for wet AMD and diabetic retinopathy.
Market Cap: $1.2B52W Range: $8.91-$47.84
Congressional Interest in Kodiak Sciences Inc. (KOD)
3 members of Congress have disclosed 7 trades in Kodiak Sciences Inc. (KOD), a Healthcare company. The buy/sell breakdown shows 5 purchases versus 2 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
7
Unique Politicians
3
Buys
5
Sells
2
Who in Congress Is Trading KOD?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-11-08 | Christopher L. Jacobs | sell | $1K-$15K |
| 2022-07-18 | Christopher L. Jacobs | buy | $1K-$15K |
| 2016-11-23 | MICHAEL T. MCCAUL | buy | $1K-$15K |
| 2016-11-22 | MICHAEL T. MCCAUL | buy | $1K-$15K |
| 2016-11-21 | MICHAEL T. MCCAUL | buy | $1K-$15K |
| 2016-11-18 | MICHAEL T. MCCAUL | buy | $1K-$15K |
| 2016-09-13 | Kurt Schrader | sell | $1K-$15K |